Andreas Rummelt

Dr. Andreas Rummelt has been a director of Alexion since February 2010. He has held executive management positions internationally for more than 20 years in the pharmaceutical industry, focused in the areas of manufacturing, quality and technical matters. He is currently the CEO and Partner of InterPharmaLink AG, a management consulting firm focused on advising companies in the healthcare industry. Dr. Rummelt was Group Head of Quality Assurance and Technical Operations at Novartis, and served as a member of the Executive Committee there. He also held various positions of increasing responsibility in development for Sandoz Pharma Ltd including CEO, Head of Worldwide Technical Research and Development, Head of Technical Operations of the Novartis Pharmaceuticals Division. He currently serves on the Board of Directors at Acino, Xellia Pharmaceuticals and Selcia, Ltd.

Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the University of Erlangen-Nuremberg, Germany. He received executive training in general management and leadership from IMD in Lausanne (Switzerland), INSEAD in Fontainebleau (France), and Harvard Business School in Cambridge (USA).

Andreas Rummelt is the Director at Alexion Pharmaceuticals. With a background in Biotechnology, Andreas Rummelt has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.